CVS Health study finds GLP-1 medical savings fall short of drug costs
- CVS Health today released research linking GLP-1 use to better clinical outcomes, fewer hospitalizations and lower medical spending.
- Medical savings did not fully offset higher pharmacy spending at current drug prices.
- Modeling suggested a net price of approximately $350 per month over three years would balance pharmacy spending with observed medical savings.
- The analysis compared commercially insured Aetna GLP-1 users with matched non-users, covering treatment starts from 2023 through 2025.
- Dr. Amy Compton-Phillips will discuss the findings later today at the HLTH industry conference in Las Vegas.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVS Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151000PR_NEWS_USPR_____NE97989) on November 15, 2026, and is solely responsible for the information contained therein.